Understanding how NCK1 influences blood cell production in certain blood disorders
Official title: The role of NCK1 in CSF3R-driven myeloproliferative neoplasms
Funded at Oregon Health & Science University · NIH-11000787 · Data updated 2026-11-12
This study is looking at how a protein called NCK1 works with a receptor that helps make white blood cells, and it aims to find new ways to treat people with blood disorders that cause too many of these cells to be produced.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31HL165919-03 |
| Project ID | NIH-11000787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with mutations in the CSF3R gene.
✕Less likely to help
Patients with blood disorders not related to CSF3R mutations or those with other types of blood cancers may not benefit from this research.
What this research studies
This research investigates the role of a protein called NCK1 in the signaling pathways activated by the Colony Stimulating Factor 3 Receptor (CSF3R), which is crucial for the production of neutrophils, a type of white blood cell. The study focuses on myeloproliferative neoplasms (MPNs), where mutations in CSF3R lead to excessive neutrophil production. By identifying how NCK1 interacts with CSF3R and influences the MAPK signaling pathway, the research aims to uncover new therapeutic targets that could improve treatment options for patients with these blood disorders.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better control blood cell production in patients with myeloproliferative neoplasms.
How similar studies have gone: Other research has shown promising results in targeting similar signaling pathways in blood disorders, suggesting that this approach may also yield beneficial outcomes.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Maniaci, Breanna Nicole — Oregon Health & Science University
- Study coordinator: Maniaci, Breanna Nicole
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.